Cointime

Innate Pharma

company

About

Innate Pharma is a biopharmaceutical company developing immunotherapy drug candidates for the treatment of cancer and inflammatory diseases.

  • 51 - 100

Highlights

Total Funding Amount
€97.60M
Funding Rounds
3
Investors
4

Details

Last Funding Type
Series C
Last Funding Money Raised
€15M
Industries
Biopharma,Biotechnology,Clinical Trials,Medical,Pharmaceutical
Founded date
Jan 1, 1999
Number Of Employee
51 - 100
Operating Status
Active

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class immunotherapy drug candidates for cancer and inflammatory diseases.

The Company specializes in the development of novel monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Its innovative approaches have led to licensing agreements with Novo Nordisk A/S and Bristol-Myers Squibb.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
€97.60M
Innate Pharma has raised a total of €97.60M in funding over 2 rounds. Their latest funding was raised on Oct 24, 2018 from a Corporate Round round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 24, 2018 Corporate Round €62.60M 1 AstraZeneca — Detail
Sep 1, 2004 Series C €15M 3 — — Detail
Jan 1, 2002 Series B €20M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
1
4
Innate Pharma is funded by 4 investors. AstraZeneca and Novo Nordisk are the most recent investors.
Investor Name Lead Investor Funding Round
AstraZeneca Yes Corporate Round
Novo Nordisk — Series C
Akka Venture — Series C
NIF SMBC Ventures — Series C
Cointime
เนื้อหา
บริษัท